| 2.6363 -0.004 (-0.14%) | 04-23 12:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.85 | 1-year : | 6.12 |
| Resists | First : | 4.15 | Second : | 5.23 |
| Pivot price | 2.78  |
|||
| Supports | First : | 2.4 | Second : | 1.99 |
| MAs | MA(5) : | 2.67 |
MA(20) : | 3.12 |
| MA(100) : | 7.37 |
MA(250) : | 7.59 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 19.5 |
D(3) : | 16.5 |
| RSI | RSI(14): 31.5 |
|||
| 52-week | High : | 48.79 | Low : | 2.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VVOS ] has closed above bottom band by 33.3%. Bollinger Bands are 92.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 61 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.73 - 2.75 | 2.75 - 2.76 |
| Low: | 2.54 - 2.55 | 2.55 - 2.57 |
| Close: | 2.62 - 2.64 | 2.64 - 2.67 |
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Tue, 09 Apr 2024
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today? - InvestorPlace
Tue, 09 Apr 2024
What's Going On With Vivos Therapeutics Stock? - Vivos Therapeutics (NASDAQ:VVOS) - Benzinga
Mon, 01 Apr 2024
Should You Buy Vivos Therapeutics Inc (VVOS) Stock Monday Morning? - InvestorsObserver
Mon, 01 Apr 2024
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 15 Feb 2024
Vivos Therapeutics Secures $8M Through Strategic Equity Deals - TipRanks.com - TipRanks
Fri, 02 Feb 2024
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 7.3 (%) |
| Held by Institutions | 13.7 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 24 (K) |
| EPS | -11.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.21 |
| Profit Margin | -98.5 % |
| Operating Margin | -127.3 % |
| Return on Assets (ttm) | -88.5 % |
| Return on Equity (ttm) | -521.3 % |
| Qtrly Rev. Growth | -17.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.63 |
| EBITDA (p.s.) | -5.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.25 |
| PEG Ratio | 0 |
| Price to Book value | 12.18 |
| Price to Sales | 0.57 |
| Price to Cash Flow | -0.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|